RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Working capital

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndWorking capital (Million USD)YoY (%)
Dec 31, 20242,402+23.98%
Dec 31, 20231,937+21.16%
Dec 31, 20221,599+23.48%
Dec 31, 20211,295+28.08%
Dec 31, 20201,011+41.71%
Dec 31, 2019713+68.63%
Dec 31, 2018423+32.55%
Dec 31, 2017319+46.93%
Dec 31, 2016217+35.85%
Dec 31, 2015160+348.94%
Dec 31, 201436-29.24%
Dec 31, 201350-30.49%
Dec 31, 201272-67.22%
Dec 31, 2011221

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)